Under vedligeholdelsesbehandlingen var hyppigheden af hjertesygdomme af grad 3/ 4 / sammenlignelig mellem patienter behandlet i MabThera- gruppen og i observationssgruppen.
Cardiac events were reported as serious adverse events (including atrial fibrillation, myocardial infarction, left ventricular failure, myocardial ischemia) in 3% of patients treated with MabThera compared to < 1% on observation.